Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Summit Therapeutics entered a clinical trial collaboration with ECOG-ACRIN to run EA2251 (NCT07765433), a registration-enabling Phase II/III study of ivonescimab plus chemotherapy versus pembrolizumab or durvalumab plus chemotherapy in first-line advanced biliary tract cancer. The open-label U.S. study has overall survival as its primary endpoint, with trial site activations expected to begin in Q4 2026; EA2251 is the second Phase III study of ivonescimab in BTC after the positive HARMONi-GI1 readout announced by Akeso in August 2026.
Key figures
- Drug Name
- ivonescimab (SMT112/AK112)
- Phase Of Trial
- Phase II/III
- Nct id
- NCT07765433
- Study name
- EA2251
- Primary endpoint
- overall survival
- Site activations
- Q4 2026
- Pdufa date harmoni bla
- November 14, 2026
- Phase3 trials of ivonescimab
- 17
- Five year survival distant stage btc
- less than 5%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.